- Home
- GLST vs LEXX Comparison
GLST vs LEXX Comparison
Compare GLST & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLST
- LEXX
- Stock Information
- Founded
- GLST 2019
- LEXX 2004
- Country
- GLST United States
- LEXX Canada
- Employees
- GLST N/A
- LEXX N/A
- Industry
- GLST Consumer Electronics/Appliances
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- GLST Industrials
- LEXX Health Care
- Exchange
- GLST Nasdaq
- LEXX Nasdaq
- Market Cap
- GLST 48.0M
- LEXX 39.1M
- IPO Year
- GLST 2022
- LEXX N/A
- Fundamental
- Price
- GLST $11.41
- LEXX $1.90
- Analyst Decision
- GLST
- LEXX Strong Buy
- Analyst Count
- GLST 0
- LEXX 2
- Target Price
- GLST N/A
- LEXX $11.00
- AVG Volume (30 Days)
- GLST 435.0
- LEXX 249.7K
- Earning Date
- GLST 01-01-0001
- LEXX 01-10-2025
- Dividend Yield
- GLST N/A
- LEXX N/A
- EPS Growth
- GLST N/A
- LEXX N/A
- EPS
- GLST N/A
- LEXX N/A
- Revenue
- GLST N/A
- LEXX $496,923.00
- Revenue This Year
- GLST N/A
- LEXX $20.39
- Revenue Next Year
- GLST N/A
- LEXX $113.25
- P/E Ratio
- GLST N/A
- LEXX N/A
- Revenue Growth
- GLST N/A
- LEXX 77.63
- 52 Week Low
- GLST $10.57
- LEXX $1.36
- 52 Week High
- GLST $12.67
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- GLST 42.34
- LEXX 37.49
- Support Level
- GLST $11.37
- LEXX $1.62
- Resistance Level
- GLST $12.20
- LEXX $2.25
- Average True Range (ATR)
- GLST 0.10
- LEXX 0.24
- MACD
- GLST -0.06
- LEXX -0.03
- Stochastic Oscillator
- GLST 6.35
- LEXX 34.57
About GLST Global Star Acquisition Inc.
Global Star Acquisition Inc is a blank check company.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.